Drug class
Immunosuppressants - Calcineurin Inhibitors
Immunosuppressants in the calcineurin inhibitor class are targeted pharmacologic agents that dampen T-cell–mediated immune responses. Read more about Immunosuppressants - Calcineurin Inhibitors
49 drugs in this class 37 manufacturers
Drugs in Immunosuppressants - Calcineurin Inhibitors
TACROLIMUS
TACROLIMUS
TACROLIMUS
TACROLIMUS
TACROLIMUS XL (tacrolimus)
TACROLIMUS
TACROLIMUS
CYCLOSPORINE
Immunosuppressants in the calcineurin inhibitor class are targeted pharmacologic agents that dampen T-cell–mediated immune responses.
They exert their therapeutic effect by binding to intracellular immunophilins, such as cyclophilin or FK-binding proteins, thereby inhibiting the phosphatase enzyme calcineurin and blocking the transcription of interleukin-2 and other essential proinflammatory cytokines.
Clinically, these agents—most notably cyclosporine, tacrolimus, and voclosporin—serve as a cornerstone in preventing and managing organ allograft rejection following solid organ transplantation.
They are also widely utilized in rheumatology, nephrology, and dermatology to treat diverse immune-mediated and inflammatory conditions, including lupus nephritis, rheumatoid arthritis, and atopic dermatitis.
-
nih.gov
Immunosuppressants in the calcineurin inhibitor class are targeted pharmacologic agents that dampen T-cell–mediated immune responses They exert their therapeutic effect by binding to intracellular immunophilins, such as cyclophilin or FK-binding proteins, thereby inhibiting the phosphatase enzyme calcineurin and blocking the transcription of interleukin-2 and other essential proinflammatory cytokines Clinically, these agents—most notably cyclosporine, tacrolimus, and voclosporin—serve as a corne...
-
nih.gov
Immunosuppressants in the calcineurin inhibitor class are targeted pharmacologic agents that dampen T-cell–mediated immune responses
-
nih.gov
They exert their therapeutic effect by binding to intracellular immunophilins, such as cyclophilin or FK-binding proteins, thereby inhibiting the phosphatase enzyme calcineurin and blocking the transcription of interleukin-2 and other essential proinflammatory cytokines
-
fda.gov
Clinically, these agents—most notably cyclosporine, tacrolimus, and voclosporin—serve as a cornerstone in preventing and managing organ allograft rejection following solid organ transplantation
-
nih.gov
Clinically, these agents—most notably cyclosporine, tacrolimus, and voclosporin—serve as a cornerstone in preventing and managing organ allograft rejection following solid organ transplantation
-
nih.gov
They are also widely utilized in rheumatology, nephrology, and dermatology to treat diverse immune-mediated and inflammatory conditions, including lupus nephritis, rheumatoid arthritis, and atopic dermatitis
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.